Cargando…

25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1

Observational studies suggest that host factors are associated with breast cancer risk. The influence of obesity, vitamin-D status, insulin resistance, inflammation, and elevated adipocytokines in women at high risk of breast cancer is unknown. The NSABP-P1 trial population was used for a nested cas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amir, Eitan, Cecchini, Reena S., Ganz, Patricia A., Costantino, Joseph P., Beddows, Samantha, Hood, Nicola, Goodwin, Pamela J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2012
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396331/ https://www.ncbi.nlm.nih.gov/pubmed/22415479 http://dx.doi.org/10.1007/s10549-012-2012-x

Ejemplares similares

Erratum to: 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1
por: Amir, Eitan, et al.
Publicado: (2012)

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide
por: Gjerde, Jennifer, et al.
Publicado: (2012)

Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
por: Swain, Sandra M., et al.
Publicado: (2019)

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
por: Ganz, Patricia A., et al.
Publicado: (2021)

Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35
por: Henry, N. Lynn, et al.
Publicado: (2021)

Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30
por: Henry, N. Lynn, et al.
Publicado: (2022)

Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
por: Calsavara, Vinicius F., et al.
Publicado: (2023)

Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial
por: Advani, Pooja P., et al.
Publicado: (2023)

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer
por: Nordenskjöld, Anna, et al.
Publicado: (2016)

Primary chemotherapy for operable breast cancer: the NSABP experience
por: Bear, HD
Publicado: (2005)

Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831
por: Pogue-Geile, Katherine L, et al.
Publicado: (2020)

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
por: van Nes, J. G. H., et al.
Publicado: (2012)

Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients
por: Binkhorst, Lisette, et al.
Publicado: (2015)

Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer
por: Souwer, E. T. D., et al.
Publicado: (2023)

Evaluation of three APBI techniques under NSABP B‐39 guidelines
por: Scanderbeg, Daniel, et al.
Publicado: (2009)

Health‐related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP R‐04
por: Ganz, Patricia A., et al.
Publicado: (2022)

Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment
por: Lien, Ernst A., et al.
Publicado: (2013)

Genetic polymorphisms of 3′-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy
por: Sanchez-Spitman, A. B., et al.
Publicado: (2018)

Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen
por: Bychkovsky, Brittany, et al.
Publicado: (2022)

Vitamin D Status and Pregnancy Complications: Serum 1,25-di-hydroxyl-Vitamin D and its Ratio to 25-hydroxy-Vitamin D are Superior Biomarkers than 25-hydroxy-Vitamin D
por: Albahlol, Ibrahim A., et al.
Publicado: (2020)

No major effects of vitamin D(3) (1,25 dihydroxyvitamin D(3)) on absorption and pharmacokinetics of folic acid and fexofenadine in healthy volunteers
por: Kullak-Ublick, Gerd A., et al.
Publicado: (2016)

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
por: Dezentjé, V. O., et al.
Publicado: (2015)

Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients
por: Thorén, Linda, et al.
Publicado: (2021)

Serum levels of 25-hydroxy vitamin D in psoriatic patients
por: Zuchi, Manuela Ferrasso, et al.
Publicado: (2015)

Plasma 25-Hydroxy Vitamin D is not Associated with Acne Vulgaris
por: Al-Taiar, Abdullah, et al.
Publicado: (2018)

Total 25-hydroxy vitamin D level in cerebrospinal fluid correlates with serum total, bioavailable, and free 25-hydroxy vitamin D levels in Korean population
por: Lee, Dong-Hyun, et al.
Publicado: (2019)

Feasibility and benefits of group-based exercise in residential aged care adults: a pilot study for the GrACE programme
por: Fien, Samantha, et al.
Publicado: (2016)

nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer
por: Hamilton, Erika, et al.
Publicado: (2022)

Does rosuvastatin increase serum levels of 25-hydroxy-vitamin D?
por: Glossmann, Hartmut H., et al.
Publicado: (2012)

Falsely Elevated 25-Hydroxy-Vitamin D Levels in Patients with Hypercalcemia
por: Choi, Moon Kyung, et al.
Publicado: (2020)

Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
por: Alkner, S., et al.
Publicado: (2017)

The Prevalence of Vitamin D and Calcium Supplement use and Association with Serum 25-Hydroxy-vitamin D (25(OH)D) and Demographic and Socioeconomic Variables in Iranian Elderly
por: Mansouri, Sara, et al.
Publicado: (2021)

The variation in free 25-hydroxy vitamin D and vitamin D-binding protein with season and vitamin D status
por: Oleröd, Göran, et al.
Publicado: (2017)

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES
por: Szijgyarto, Zsolt, et al.
Publicado: (2019)

The Relationship Between Serum 25 Hydroxy Vitamin D Levels and Asthma in Children
por: Alyasin, Soheila, et al.
Publicado: (2011)

25-Hydroxy vitamin D levels and endothelial vasodilator function in normotensive women
por: Ertek, Sibel, et al.
Publicado: (2012)

Carbon cloth-based immunosensor for detection of 25-hydroxy vitamin D(3)
por: Chauhan, Deepika, et al.
Publicado: (2021)

Serum 25-hydroxy vitamin D levels in age-related macular degeneration
por: Pérez Serena, Antonio, et al.
Publicado: (2022)

Differences in 25-hydroxy vitamin D and vitamin D-binding protein concentrations according to the severity of endometriosis
por: Baek, Jong Chul, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_499g3qnd95etdu5h9btc75ud3u